Small Molecule Screening and Medicinal Chemistry Core

小分子筛选和药物化学核心

• 批准号: 8233438
• 负责人: STEPHEN LORY
• 金额: $ 88.23万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8233438
• 关键词: Affect; Biological; Biological Process; Clinical; Communicable Diseases; Complex; Data; Data Analyses; Emerging Communicable Diseases; Funding; Goals; Grant; Infection; Laboratories; Lead; Libraries; Methods; Molecular Probes; National Institute of Allergy and Infectious Disease; Natural Immunity; New England; Pathway interactions; Pharmaceutical Chemistry; Publications; Reagent; Research; Research Personnel; Resources; Screening procedure; Therapeutic; United States National Institutes of Health; adaptive immunity; antimicrobial drug; biodefense; drug discovery; high throughput screening; microbial; novel; novel therapeutics; pathogen; prevent; programs; small molecule; therapeutic development; tool

High-throughput screening (HTS) of libraries with large numbers of small molecules is a widely recognized and increasingly used method for identifying compounds that modulate biological processes. Compounds thus identified can be powerful molecular probes for dissecting complex biological pathways, and may also be potential leads for clinical use. In the context of biodefense and emerging infectious disease, small molecule HTS could lead to the discovery of new classes of antimicrobial agents or novel stimulators of innate or adaptive immunity, and also identify and validate novel targets for subsequent drug discovery efforts. The National Small Molecule Screening Laboratory for the RCEs in Biodefense and Emerging Infectious Disease (NSRB) was established in 2003 to provide access to small molecule high-throughput screening (HTS) and medicinal chemistry resources for all U.S. investigators conducting research on NIAID Priority Pathogens. It has been a highly successful program and several NSRB projects have produced reagents that are progressing toward possible therapeutic development. The NERCE National Small Molecule Screening and Medicinal Chemistry Core (Core C) propsed here is a continuation of the NSRB. The main goals for Core C are to: Provide access to small-molecule HTS for all U.S. investigators with projects focused on NIAID Priority Pathogens and agents of Emerging Infectious Diseases, and to Provide data analysis and medicinal chemistry resources for maturation of screening positives into smallmolecule research tools or into potential novel therapeutic leads.

具有大量小分子的文库的高通量筛选（HTS）是广泛认可的方法。 并且越来越多地用于鉴定调节生物过程的化合物的方法。化合物 因此，所鉴定的可以是用于解剖复杂生物途径的强有力的分子探针，并且还可以 成为临床应用的潜在线索。在生物防御和新兴传染病的背景下， 分子HTS可能导致发现新类别的抗微生物剂或新的刺激剂， 先天性或适应性免疫，并为后续药物发现鉴定和验证新靶点 努力 国家小分子筛选实验室的RCEs在生物防御和新兴传染病 疾病（NSRB）成立于2003年，提供小分子高通量筛查 (HTS)和药物化学资源，供所有从事NIAID优先研究的美国研究人员使用 病原体这是一个非常成功的计划，几个NSRB项目已经生产了试剂 正在朝着可能的治疗发展。 NERCE国家小分子筛选和药物化学核心（核心C）是一个 NSRB的延续。核心C的主要目标是： 为所有从事NIAID优先项目的美国研究人员提供小分子HTS 新出现的传染病的病原体和病原体，以及 提供数据分析和药物化学资源，以使筛选阳性药物成熟为小分子药物 研究工具或潜在的新的治疗线索。